No compounds match the current filters.
Clear filtersGLP-1, GIP, glucagon:
which trial path?
Single-pathway GLP-1 agonists like Semaglutide remain the most studied class for metabolic research. Tirzepatide and Retatrutide expand the receptor profile — dual and triple agonists with distinct downstream effects worth comparing in your protocol design.
Read the science noteMISSING FROM THE BENCH?
Can't find the research compound you were looking for? Submit a request and we'll let you know if it's added to the NZM lineup.
Requests help us prioritize future batches — every added compound still goes through our sourcing and verification process.